DE2805663B2 - Verfahren zur Herstellung von Antigenen und deren Verwendung zur Herstellung von Antikörpern - Google Patents
Verfahren zur Herstellung von Antigenen und deren Verwendung zur Herstellung von AntikörpernInfo
- Publication number
- DE2805663B2 DE2805663B2 DE2805663A DE2805663A DE2805663B2 DE 2805663 B2 DE2805663 B2 DE 2805663B2 DE 2805663 A DE2805663 A DE 2805663A DE 2805663 A DE2805663 A DE 2805663A DE 2805663 B2 DE2805663 B2 DE 2805663B2
- Authority
- DE
- Germany
- Prior art keywords
- glucagon
- antibody
- antibodies
- pancreatic
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims description 44
- 108091007433 antigens Proteins 0.000 title claims description 44
- 102000036639 antigens Human genes 0.000 title claims description 44
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 238000000034 method Methods 0.000 title description 24
- 230000008569 process Effects 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims description 6
- 229960004666 glucagon Drugs 0.000 description 103
- 102000051325 Glucagon Human genes 0.000 description 98
- 108060003199 Glucagon Proteins 0.000 description 96
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 16
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 108010045362 Serum Globulins Proteins 0.000 description 8
- 102000005686 Serum Globulins Human genes 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 241000131390 Glis Species 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 241000473945 Theria <moth genus> Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000000813 peptide hormone Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101800002372 Motilin Proteins 0.000 description 3
- 102400001357 Motilin Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- -1 malonic acid aldehyde Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940108519 trasylol Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- JMSONHOUHFDOJH-GUBZILKMSA-N His-Ser-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 JMSONHOUHFDOJH-GUBZILKMSA-N 0.000 description 1
- 101001002317 Homo sapiens Gastrin Proteins 0.000 description 1
- 101500028775 Homo sapiens Glucagon Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 108700020479 Pancreatic hormone Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 1
- YLGQHMHKAASRGJ-WDSOQIARSA-N Trp-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N YLGQHMHKAASRGJ-WDSOQIARSA-N 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP52013919A JPS5836308B2 (ja) | 1977-02-10 | 1977-02-10 | 抗体の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2805663A1 DE2805663A1 (de) | 1978-08-17 |
| DE2805663B2 true DE2805663B2 (de) | 1980-03-13 |
| DE2805663C3 DE2805663C3 (enExample) | 1980-11-13 |
Family
ID=11846569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2805663A Granted DE2805663B2 (de) | 1977-02-10 | 1978-02-10 | Verfahren zur Herstellung von Antigenen und deren Verwendung zur Herstellung von Antikörpern |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US4221777A (enExample) |
| JP (1) | JPS5836308B2 (enExample) |
| BE (1) | BE863810A (enExample) |
| DE (1) | DE2805663B2 (enExample) |
| DK (1) | DK157340C (enExample) |
| FR (1) | FR2380296A1 (enExample) |
| GB (1) | GB1580582A (enExample) |
| SE (1) | SE427931B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5539702A (en) * | 1978-08-30 | 1980-03-19 | Takeda Chem Ind Ltd | Method of measuring enzyme immunity of pancreas glucagon |
| JPS5657753A (en) * | 1979-10-16 | 1981-05-20 | Toyo Jozo Co Ltd | Novel glucagon fragment, and its use |
| US4376765A (en) * | 1980-03-31 | 1983-03-15 | Institut International De Pathologie Cellulaire Et Moleculaire | Medicaments, their preparation and compositions containing same |
| JPS56163456A (en) * | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| DK283180A (da) * | 1980-07-01 | 1982-01-02 | Novo Industri As | Polypeptider og derivater deraf |
| JPS5735551A (en) * | 1980-08-08 | 1982-02-26 | Daiichi Rajio Isotope Kenkyusho:Kk | Preparation of undecapeptide |
| US4430326A (en) | 1981-12-22 | 1984-02-07 | University Patents, Inc. | Method of diminishing glucose levels resulting from endogenous glucagon |
| FR2525592B1 (enExample) * | 1982-04-26 | 1984-09-14 | Pasteur Institut | |
| US4487715A (en) * | 1982-07-09 | 1984-12-11 | The Regents Of The University Of California | Method of conjugating oligopeptides |
| US4591552A (en) * | 1982-09-29 | 1986-05-27 | New York Blood Center, Inc. | Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide |
| EP0134868A1 (en) * | 1983-08-26 | 1985-03-27 | Anda Biologicals | Unicellular organisms activated by glutaraldehyde as solid carriers for sensitizing agents and uses of sensitized unicellular organisms |
| CA1256795A (en) * | 1983-12-28 | 1989-07-04 | Dennis A. Carson | Anti-idiotype antibodies induced by synthetic polypeptides |
| US4666884A (en) * | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| US4617376A (en) * | 1985-07-01 | 1986-10-14 | Eli Lilly And Company | Process for recovering glucagon from pancreas glands |
| US4731439A (en) * | 1985-11-22 | 1988-03-15 | Oncogen | Snake venom growth arresting peptide |
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5176227A (en) * | 1991-08-01 | 1993-01-05 | Tec Tran Corporation | Railway service and parking brake actuator |
| US5253736A (en) * | 1991-08-01 | 1993-10-19 | Tec Tran Corporation | Railway brake actuator |
| US20050009205A1 (en) * | 2003-07-11 | 2005-01-13 | Ye Fang | Fluorescent ligands for GPCR arrays |
| BR112017005110A2 (pt) | 2014-09-16 | 2018-01-23 | Regeneron Pharma | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. |
| KR102708864B1 (ko) | 2016-08-30 | 2024-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 |
| EP3529278A1 (en) | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| JP7781519B2 (ja) | 2017-08-22 | 2025-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| CN114410590B (zh) * | 2022-01-27 | 2024-01-09 | 广州市进德生物科技有限公司 | 一种分泌胰高血糖素单克隆抗体杂交瘤细胞株及其单克隆抗体与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3553310A (en) * | 1967-12-28 | 1971-01-05 | Miles Lab | Immunologically reactive particles |
| CH564031A5 (enExample) * | 1968-03-29 | 1975-07-15 | Anvar | |
| GB1282163A (en) * | 1969-08-06 | 1972-07-19 | Beecham Group Ltd | Modified allergens and a process for their preparation |
| US3975342A (en) * | 1972-05-15 | 1976-08-17 | Biological Developments, Inc. | Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto |
| US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4075194A (en) * | 1976-12-09 | 1978-02-21 | Yeda Research And Development Co., Ltd. | Novel synthetic undecapeptide and clinical assay |
-
1977
- 1977-02-10 JP JP52013919A patent/JPS5836308B2/ja not_active Expired
-
1978
- 1978-02-09 DK DK059778A patent/DK157340C/da not_active IP Right Cessation
- 1978-02-09 SE SE7801545A patent/SE427931B/sv not_active IP Right Cessation
- 1978-02-09 BE BE185040A patent/BE863810A/xx not_active IP Right Cessation
- 1978-02-10 GB GB5388/78A patent/GB1580582A/en not_active Expired
- 1978-02-10 FR FR7803905A patent/FR2380296A1/fr active Granted
- 1978-02-10 DE DE2805663A patent/DE2805663B2/de active Granted
- 1978-07-13 US US05/924,319 patent/US4221777A/en not_active Expired - Lifetime
-
1979
- 1979-09-20 US US06/077,221 patent/US4272433A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BE863810A (fr) | 1978-05-29 |
| DE2805663A1 (de) | 1978-08-17 |
| DK157340B (da) | 1989-12-18 |
| SE7801545L (sv) | 1978-08-11 |
| US4272433A (en) | 1981-06-09 |
| US4221777A (en) | 1980-09-09 |
| JPS5836308B2 (ja) | 1983-08-08 |
| DK157340C (da) | 1990-05-14 |
| FR2380296A1 (fr) | 1978-09-08 |
| JPS5399320A (en) | 1978-08-30 |
| GB1580582A (en) | 1980-12-03 |
| SE427931B (sv) | 1983-05-24 |
| DE2805663C3 (enExample) | 1980-11-13 |
| DK59778A (da) | 1978-08-11 |
| FR2380296B1 (enExample) | 1981-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2805663C3 (enExample) | ||
| DE69032833T2 (de) | Diagnose und behandlung von insulinabhängigem diabetes mellitus | |
| DE2202441B2 (de) | Barbitursäureantigene und spezifische Antikörper hierfür | |
| DE2744983A1 (de) | Mehrwertiger antigen-protein-komplex | |
| DE3785038T2 (de) | Monoklonale antikoerper gegen nicht reduzierte, nicht enzymatisch glykolysierte proteine. | |
| EP0013930B1 (de) | Immunogen, Antikörper für ein Thymus-Hormon, markiertes Thymus-Hormon und Verfahren zur Bestimmung dieses Thymushormons | |
| DE1927209A1 (de) | Acyl-substituierte Insuline und Verfahren zu ihrer Herstellung | |
| DE3751316T2 (de) | Materialzusammensetzung, welche ein Polypeptid aus Pankreas-Insel-Amyloid und/oder Antikörpern gegen dieses Polypeptid enthält, und Anwendung dieser Zusammensetzung. | |
| DD296933A5 (de) | Peptide | |
| DE2219635A1 (de) | Insulinprodukt | |
| EP3346273B1 (de) | Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung | |
| DE3851455T2 (de) | Biologisch wirksame Moleküle. | |
| DE3879085T2 (de) | Snrnp-a-antigen und fragmente davon. | |
| DE68917061T2 (de) | O-glycosylierter IGF-1. | |
| DE2608096A1 (de) | Antigene und verfahren zu ihrer herstellung | |
| DE60035267T2 (de) | Verfahren zur analyse der menge an intraabdominalem fettgewebe | |
| EP0124779A2 (de) | Radioimmunverfahren für Thymosin beta 4 | |
| DE68927283T2 (de) | HCG-Peptide zur Verwendung in Antikörper-Reinigungsverfahren | |
| DE2310280A1 (de) | Tubocurarin-antigene | |
| DE2364883C2 (de) | Des-Lys&uarr;2&uarr;&uarr;9&uarr;-Ala&uarr;3&uarr;&uarr;0&uarr;-Schweine- und -Rinderinsulin, Verfahren zu deren Herstellung und diese Insuline enthaltende injizierbare Präparate | |
| DE3014582C2 (enExample) | ||
| DE2710455C2 (de) | N-Acetylmuramyl-L-alanyl-D-glutaminsäure-alpha-methylamid, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel | |
| DE2738156A1 (de) | Bestimmung von catecholaminen | |
| EP0420043B1 (de) | Antikörper gegen hochkonservierte Aminosäuresequenzen von immunogenen Substanzen, Verfahren zur Herstellung dieser Antikörper, sowie deren Verwendung in Immunoassays | |
| DE2126128A1 (de) | Medizinisches Testverfahren, Reagens und Additiv zur Durchführung des Verfahrens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OAP | Request for examination filed | ||
| OD | Request for examination | ||
| C3 | Grant after two publication steps (3rd publication) |